Prevalence and severity of corona virus disease 2019 (COVID-19): a systematic review and meta-analysis

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorHu, Yong-
Autor(es): dc.creatorSun, Jiazhong-
Autor(es): dc.creatorDai, Zhe-
Autor(es): dc.creatorDeng, Haohua-
Autor(es): dc.creatorLi, Xin-
Autor(es): dc.creatorHuang, Qi-
Autor(es): dc.creatorWu, Yuwen-
Autor(es): dc.creatorSun, Li-
Autor(es): dc.creatorXu, Yancheng-
Data de aceite: dc.date.accessioned2026-02-09T12:25:46Z-
Data de disponibilização: dc.date.available2026-02-09T12:25:46Z-
Data de envio: dc.date.issued2020-08-20-
Data de envio: dc.date.issued2020-08-20-
Data de envio: dc.date.issued2020-06-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/42498-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S138665322030113X-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1161135-
Descrição: dc.descriptionBackground Since being first reported in Wuhan, China, in December 8, 2019, the outbreak of the novel coronavirus, now known as COVID-19, has spread globally. Some case studies regarding the characteristics and outcome of patients with COVID-19 have been published recently. We conducted a meta-analysis to evaluate the risk factors of COVID-19. Methods Medline, SinoMed, EMBASE, and Cochrane Library were searched for clinical and epidemiological studies on confirmed cases of COVID-19. Results The incidence of fever, cough, fatigue, and dyspnea symptoms were 85.6 % (95CI 81.3–89.9 %), 65.7 % (95CI 60.1–71.4 %), 42.4 % (95CI 32.2–52.6 %) and 21.4 % (95CI 15.3–27.5 %). The prevalence of diabetes was 7.7 % (95CI 6.1–9.3 %), hypertension was 15.6 % (95CI 12.6–18.6 %), cardiovascular disease was 4.7 % (95CI 3.1–6.2 %), and malignancy was 1.2 % (95CI 0.5–1.8 %). The complications, including ARDS risk, ranged from 5.6–13.2 %, with the pooled estimate of ARDS risk at 9.4 %, ACI at 5.8 % (95CI 0.7–10.8 %), AKI at 2.1 % (95CI 0.6–3.7 %), and shock at 4.7 % (95CI 0.9–8.6 %). The risks of severity and mortality ranged from 12.6 to 23.5% and from 2.0 to 4.4 %, with pooled estimates at 18.0 and 3.2 %, respectively. The percentage of critical cases in diabetes and hypertension was 44.5 % (95CI 27.0–61.9 %) and 41.7 % (95CI 26.4–56.9 %), respectively. Conclusion Fever is the most common symptom in patients with COVID-19. The most prevalent comorbidities are hypertension and diabetes which are associated with the severity of COVID-19. ARDS and ACI may be the main obstacles for patients to treatment recovery. The case severe rate and mortality is lower than that of SARS and MERS.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceJournal of Clinical Virology-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectComorbidities-
Palavras-chave: dc.subjectSymptom-
Palavras-chave: dc.subjectMortality-
Título: dc.titlePrevalence and severity of corona virus disease 2019 (COVID-19): a systematic review and meta-analysis-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.